Phase 2 Trial Assessing CPI-1205, Plus Xtandi, Begins Dosing Metastatic CRPC Patients

Phase 2 Trial Assessing CPI-1205, Plus Xtandi, Begins Dosing Metastatic CRPC Patients
Constellation Pharmaceuticals has begun patient dosing in the second part of a Phase 1b/2 trial testing its investigational inhibitor CPI-1205, in combination with Xtandi (enzalutamide), for the second-line treatment of metastatic castration-resistant prostate cancer patients (mCRPC), the company announced. The ProSTAR trial (NCT03480646) was also expanded to include a third group in its Phase 2 part, which will test a combination of CPI-1205 plus Zytiga (abiraterone acetate) and prednisone in a similar patient population. The trial is continuing to recruit patients at sites across the U.S. The decisions come after encouraging Phase 1b results, where CPI-1205 was well-tolerated by patients and showed preliminary signs of effectiveness. “We are pleased that CPI-1205 achieved its Phase 1b endpoints in ProSTAR, demonstrating an encouraging safety profile and evidence of clinical acti
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *